Articles Tagged With: aspirin
-
USPSTF Recommends Against Using Aspirin as a Heart Attack Prevention Tool
Instead of protecting against various cardiovascular ailments, the drug might cause more harm than good in otherwise healthy older patients.
-
Anticoagulation Plus Antiplatelet Therapy in Chronic Atherosclerosis
An analysis of the COMPASS trial for the secondary endpoint of mortality showed the combination of low-dose rivaroxaban and aspirin significantly lowered the all-cause mortality rate vs. low-dose aspirin alone.
-
Anticoagulation Plus Antiplatelet Therapy in Chronic Atherosclerosis
An analysis of the COMPASS trial for the secondary endpoint of mortality showed the combination of low-dose rivaroxaban and aspirin significantly lowered the all-cause mortality rate vs. low-dose aspirin alone. -
Aspirin, Clopidogrel, or Both After Coronary Interventions?
A recent study of patients who had undergone a percutaneous coronary intervention and were transitioning from dual antiplatelet therapy to monotherapy showed clopidogrel was superior to aspirin for preventing further major adverse events, including bleeding. -
Ticagrelor, a New Antiplatelet Agent, Shows Promise in Secondary Prevention of Ischemic Stroke
Ticagrelor is an antiplatelet agent that works by reversibly binding to P2Y12 adenosine diphosphate receptors on platelets, similar to the mechanism of action of clopidogrel. However, it is a direct-acting drug, and not a pro-drug, and does not need to be enzymatically converted to be active, like clopidogrel.
-
Preventing Recurrent Stroke or Death After Ischemic Stroke, TIAs
The combination of ticagrelor and aspirin compared to aspirin alone was superior in reducing the risk of stroke or death within 30 days of an acute ischemic stroke or transient ischemic attack.
-
Disability After Minor Stroke and TIA — Secondary Analysis of the POINT Trial
Although the data from this analysis suggest disability might be less with dual antiplatelet therapy, differences between the groups were small, did not show robust findings, and did not reach statistical significance in most of the analyses.
-
Optimal Antithrombic Therapy After PCI for Atrial Fibrillation Patients
In three subgroups of coronary artery disease patients with atrial fibrillation, apixaban plus a P2Y12 inhibitor provided superior safety and similar efficacy outcomes as treatment with warfarin, aspirin, or both for six months.
-
Optimal Antithrombic Therapy After PCI for Atrial Fibrillation Patients
In three subgroups of coronary artery disease patients with atrial fibrillation, apixaban plus a P2Y12 inhibitor provided superior safety and similar efficacy outcomes as treatment with warfarin, aspirin, or both for six months.
-
Dual Antiplatelet Therapy Results in Increase in Serious Hemorrhages Following TIA or Minor Stroke